Myelofibrosis (MF)

''Myelofibrosis is a serious bone marrow disorder that disrupts your body's normal production of blood cells. The result is extensive scarring in your bone marrow, leading to severe anemia, weakness, fatigue, and often, an enlarged spleen and liver.''
Definition by Mayo Clinic staff

Improving a Breakthrough: Combination  Therapies with JAK Inhibitors
April 29, 2013, Patient  Power

Developments in Myelofibrosis: Ongoing Trials and the Significance of Mutations
December 19, 2012,  Patient  Power

Betty Brantley: A Newly Diagnosed Myelofibrosis Patient With High  Hopes
December 13, 2012, Patient   Power

The Significant Advancement in Myelofibrosis Symptom Management
November 15, 2012, Patient  Power

Jakafi®(ruxolitinib) -- Mechanism of Action (MOA) Video
August 8, 2012, Jakafi·

Myelofibrosis and Bone Marrow Transplant - Mayo  Clinic
July 19, 2012, Mayo  Clinic

Myelofibrosis 2012 Update - Mayo Clinic
March 12, 2012, Mayo Clinic

Drug Improves Quality of Life, Extends Survival for Myelofibrosis
March 9, 2012, MD Anderson Cancer Center

Dr. Mesa Discusses JAK Inhibitors for Myelofibrosis
March 2, 2012, OncLiveTV

Update on JAK Inhibitor — Spleen Volume  Reduction and OS - Serge Verstovsek, MD, PhD.
January  27, 2012, OncUViewTV

Pediatric Myelofibrosis
January 16, 2012, Medscape

Dr. Hugh-Jones Discusses the JAK2 Inhibitor SAR302503
December  13, 2011, OncLiveTV

FDA Approves Jakafi
November 16, 2011, Drugs.com

FDA Approves Ruxolitinib For Treatment of Intermediate and High Risk Myelofibrosis
November 16, 2011, Hematology.org

Myelofibrosis Research Update - Mayo Clinic
August 10. 2011, Mayo Clinic

Sonali Smith, MD: An Introduction to Myelofibrosis at ASCO 2011
July 17, 2011, vitaloptions

JAK Inhibitor Ruxolitinib COMFORT-II Trial Shows Positive Results
June 20, 2011, OncUViewTV

What Do Patients with Myelofibrosis Need  to Know?
June 3, 2011,  OncUViewTV 

Myelofibrosis - Mayo Clinic
May 10. 2011, Mayo Clinic

Myelofibrosis in 2011 - MayoClinic
January 25. 2011, Mayo Clinic

INC424 (INCB018424) An oral, Janus kinase (JAK) inhibitor selective for JAK1 and JAK2
2011, Novartis Oncology

CYT387: Potent Dual Inhibitor of JAK 1/2 in Phase I/II Clinical Development (YM BioSciences Inc.)
November 4, 2010, ymbiosciences

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
September 16, 2010, The New England Journal of Medicine

Myelofibrosis Treatment
September 15, 2010, Insidermedicine In Depth

New Drug Provides Rapid, Lasting Relief for Myelofibrosis Patients
September 15, 2010, mdandersonorg

Myelofibrosis Update - Dr. Ruben Mesa
May 17,2010, Mayo Clinic

ASH2009: JAK Inhibitor Shows Promise in Myelofibrosis December 2009, MedPage Today

Dr. Ruben Mesa discusses the symptoms, treatment and research being conducted for Myelofibrosis.
July 19, 2009, Mayo Clinic

.
.

VIDEO


VIDEO



VIDEO

fff
VIDEO


VIDEO

VIDEO


VIDEO


VIDEO


VIDEO



VIDEO




VIDEO






DEO
VIDEO


VIDEO


VIDEO


VIDEO


VIDEO
VIDEO
VIDEO


   



VIDEO



         



VIDEO


VIDEO


VIDEO


VIDEO


VIDEO

  

                See our disclaimer - Voir notre avis de non-responsabilité